TY - JOUR
T1 - Supporting dialysis policy for end stage renal disease (ESRD) in Indonesia
T2 - an updated cost-effectiveness model
AU - Putri, Septiara
AU - Nugraha, Ryan R.
AU - Pujiyanti, Eka
AU - Thabrany, Hasbullah
AU - Hasnur, Hanifah
AU - Istanti, Novita D.
AU - Evasari, Diah
AU - Afiatin,
N1 - Funding Information:
This study was funded by Baxter Indonesia with agreement letter CHEPS-18122015/Baxter. Baxter Indonesia had no intervention on study design, data collection, analysis, and interpretation. The funder also had no role for influencing the result and discussion in this paper. All authors worked independently for this study.
Funding Information:
We would like to thank all staffs and data collectors from Cikini Hospital, Hasan Sadikin Hospital, and Tarakan Hospital. We also thank the Center for Health Financing and Department, Ministry of Health Republic of Indonesia and PERNEFRI (Indonesia Association of Nephrology) who provided insightful inputs during our initial dissemination from this study.
Publisher Copyright:
© 2022, The Author(s).
PY - 2022/12
Y1 - 2022/12
N2 - Objective: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. Results: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).
AB - Objective: Continuous ambulatory peritoneal dialysis (CAPD) and hemodialysis (HD) are main modalities for end stage renal disease (ESRD) patients, and those have been covered by National Health Insurance (NHI) scheme since 2014 in Indonesia. This study aims to update the cost-effectiveness model of CAPD versus HD in Indonesia setting. Results: Compared to HD, CAPD provides good value for money among ESRD patients in Indonesia. Using societal perspective, the total costs were IDR 1,348,612,118 (USD 95,504) and IDR 1,368,447,750 (USD 96,908), for CAPD and HD, respectively. The QALY was slightly different between two modalities, 4.79 for CAPD versus 4.22 for HD. The incremental cost-effectiveness ratio (ICER) yields savings of IDR 34,723,527/QALY (USD 2460).
KW - Cost-effectiveness
KW - End stage renal disease
KW - Hemodialysis
KW - Peritoneal dialysis
UR - http://www.scopus.com/inward/record.url?scp=85143382270&partnerID=8YFLogxK
U2 - 10.1186/s13104-022-06252-4
DO - 10.1186/s13104-022-06252-4
M3 - Article
C2 - 36474238
AN - SCOPUS:85143382270
SN - 1756-0500
VL - 15
JO - BMC Research Notes
JF - BMC Research Notes
IS - 1
M1 - 359
ER -